EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 28 / No 12 (Décembre 2012) Med Sci (Paris), 28 12 (2012) 1087-1094 References
Free Access
Issue
Med Sci (Paris)
Volume 28, Number 12, Décembre 2012
Page(s) 1087 - 1094
Section M/S Revues
DOI https://doi.org/10.1051/medsci/20122812019
Published online 21 December 2012
  1. Jangouk P, Zackowski KM, Naidu S, Raymond GV. Adrenoleukodystrophy in female heterozygotes: underrecognized and undertreated. Mol Genet Metab 2012 ; 105 : 180–185. [CrossRef] [PubMed] [Google Scholar]
  2. Kemp S, Wanders R. Biochemical aspects of X-linked adrenoleukodystrophy. Brain Pathol 2010 ; 20 : 831–837. [CrossRef] [PubMed] [Google Scholar]
  3. Mosser J, Douar AM, Sarde CO, et al. Putative X-linked adrenoleukodystrophy gene shares unexpected homology with ABC transporters. Nature 1993 ; 361 : 726–730. [CrossRef] [PubMed] [Google Scholar]
  4. Dean M, Rzhetsky A, Allikmets R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res 2001 ; 11 : 1156–1166. [CrossRef] [PubMed] [Google Scholar]
  5. Kemp S, Theodoulou FL, Wanders RJ. Mammalian peroxisomal ABC transporters: from endogenous substrates to pathology and clinical significance. Br J Pharmacol 2011 ; 164 : 1753–1766. [CrossRef] [PubMed] [Google Scholar]
  6. Wanders RJ, Waterham HR. Biochemistry of mammalian peroxisomes revisited. Annu Rev Biochem 2006 ; 75 : 295–332. [CrossRef] [PubMed] [Google Scholar]
  7. Pujol A, Hindelang C, Callizot N, et al. Late onset neurological phenotype of the X-ALD gene inactivation in mice: a mouse model for adrenomyeloneuropathy. Hum Mol Genet 2002 ; 11 : 499–505. [CrossRef] [PubMed] [Google Scholar]
  8. van Roermund CW, Visser WF, Ijlst L, et al. The human peroxisomal ABC half transporter ALDP functions as a homodimer and accepts acyl-CoA esters. Faseb J 2008 ; 22 : 4201–4208. [CrossRef] [PubMed] [Google Scholar]
  9. Kemp S, Wei HM, Lu JF, et al. Gene redundancy and pharmacological gene therapy: implications for X-linked adrenoleukodystrophy. Nat Med 1998 ; 4 : 1261–1268. [CrossRef] [PubMed] [Google Scholar]
  10. Netik A, Forss-Petter S, Holzinger A, et al. Adrenoleukodystrophy-related protein can compensate functionally for adrenoleukodystrophy protein deficiency (X-ALD): implications for therapy. Hum Mol Genet 1999 ; 8 : 907–913. [CrossRef] [PubMed] [Google Scholar]
  11. Pujol A, Ferrer I, Camps C, et al. Functional overlap between ABCD1 (ALD) and ABCD2 (ALDR) transporters: a therapeutic target for X-adrenoleukodystrophy. Hum Mol Genet 2004 ; 13 : 2997–3006. [CrossRef] [PubMed] [Google Scholar]
  12. van Roermund CW, Visser WF, Ijlst L, et al. Differential substrate specificities of human ABCD1 and ABCD2 in peroxisomal fatty acid beta-oxidation. Biochim Biophys Acta Mol Cell Biol Lipids 2010 ; 1811 : 148–152. [CrossRef] [Google Scholar]
  13. Fourcade S, Ruiz M, Camps C, et al. A key role for the peroxisomal ABCD2 transporter in fatty acid homeostasis. Am J Physiol Endocrinol Metab 2009 ; 296 : E211–E221. [CrossRef] [PubMed] [Google Scholar]
  14. Genin EC, Geillon F, Gondcaille C, et al. Substrate specificity overlap and interaction between adrenoleukodystrophy protein (ALDP/ABCD1) and adrenoleukodystrophy-related protein (ALDRP/ABCD2). J Biol Chem 2011 ; 286 : 8075–8085. [CrossRef] [PubMed] [Google Scholar]
  15. Gärtner J, Moser H, Valle D. Mutations in the 70K peroxisomal membrane protein gene in Zellweger syndrome. Nat Genet 1992 ; 1 : 16–23. [CrossRef] [PubMed] [Google Scholar]
  16. Liu LX, Janvier K, Berteaux-Lecellier V, et al. Homo- and heterodimerization of peroxisomal ATP-binding cassette half-transporters. J Biol Chem 1999 ; 274 : 32738–32743. [CrossRef] [PubMed] [Google Scholar]
  17. Lombard-Platet G, Savary S, Sarde CO, et al. A close relative of the adrenoleukodystrophy (ALD) gene codes for a peroxisomal protein with a specific expression pattern. Proc Natl Acad Sci USA 1996 ; 93 : 1265–1269. [CrossRef] [Google Scholar]
  18. Berger J, Albet S, Bentejac M, et al. The four murine peroxisomal ABC-transporter genes differ in constitutive, inducible and developmental expression. Eur J Biochem 1999 ; 265 : 719–727. [CrossRef] [PubMed] [Google Scholar]
  19. Bottelbergs A, Verheijden S, Hulshagen L, et al. Axonal integrity in the absence of functional peroxisomes from projection neurons and astrocytes. Glia 2010 ; 58 : 1532–1543. [PubMed] [Google Scholar]
  20. Singh I, Pujol A. Pathomechanisms underlying X-adrenoleukodystrophy: a three-hit hypothesis. Brain Pathol 2010 ; 20 : 838–844. [CrossRef] [PubMed] [Google Scholar]
  21. Deon M, Sitta A, Barschak AG, et al. Induction of lipid peroxidation and decrease of antioxidant defenses in symptomatic and asymptomatic patients with X-linked adrenoleukodystrophy. Int J Dev Neurosci 2007 ; 25 : 441–444. [CrossRef] [PubMed] [Google Scholar]
  22. Uto T, Contreras MA, Gilg AG, Singh I. Oxidative imbalance in nonstimulated X-adrenoleukodystrophy-derived lymphoblasts. Dev Neurosci 2008 ; 30 : 410–418. [CrossRef] [PubMed] [Google Scholar]
  23. Fourcade S, Ruiz M, Guilera C, et al. Valproic acid induces antioxidant effects in X-linked adrenoleukodystrophy. Hum Mol Genet 2010 ; 19 : 2005–2014. [CrossRef] [PubMed] [Google Scholar]
  24. Paintlia AS, Gilg AG, Khan M, et al. Correlation of very long chain fatty acid accumulation and inflammatory disease progression in childhood X-ALD: implications for potential therapies. Neurobiol Dis 2003 ; 14 : 425–439. [CrossRef] [PubMed] [Google Scholar]
  25. Khan M, Singh J, Gilg AG, et al. Very long-chain fatty acid accumulation causes lipotoxic response via 5-lipoxygenase in cerebral adrenoleukodystrophy. J Lipid Res 2010 ; 51 : 1685–1695. [CrossRef] [PubMed] [Google Scholar]
  26. Galino J, Ruiz M, Fourcade S, et al. Oxidative damage compromises energy metabolism in the axonal degeneration mouse model of X-adrenoleukodystrophy. Antioxid Redox Signal 2011 ; 15 : 2095–2107. [CrossRef] [PubMed] [Google Scholar]
  27. Singh J, Khan M, Singh I. Silencing of Abcd1 and Abcd2 genes sensitizes astrocytes for inflammation: implication for X-adrenoleukodystrophy. J Lipid Res 2009 ; 50 : 135–147. [CrossRef] [PubMed] [Google Scholar]
  28. Baarine M, Andreoletti P, Athias A, et al. Evidence of oxidative stress in very long chain fatty acid-treated oligodendrocytes and potentialization of ROS production using RNA interference-directed knockdown of ABCD1 and ACOX1 peroxisomal proteins. Neuroscience 2012 ; 213 : 1–18. [CrossRef] [PubMed] [Google Scholar]
  29. Moser HW, Raymond GV, Lu SE, et al. Follow-up of 89 asymptomatic patients with adrenoleukodystrophy treated with Lorenzo’s oil. Arch Neurol 2005 ; 62 : 1073–1080. [CrossRef] [PubMed] [Google Scholar]
  30. Fourcade S, Savary S, Gondcaille C, et al. Thyroid hormone induction of the adrenoleukodystrophy-related gene (ABCD2). Mol Pharmacol 2003 ; 63 : 1296–1303. [CrossRef] [PubMed] [Google Scholar]
  31. Genin EC, Gondcaille C, Trompier D, Savary S. Induction of the adrenoleukodystrophy-related gene (ABCD2) by thyromimetics. J Steroid Biochem Mol Biol 2009 ; 116 : 37–43. [CrossRef] [PubMed] [Google Scholar]
  32. Gondcaille C, Depreter M, Fourcade S, et al. Phenylbutyrate up-regulates the adrenoleukodystrophy-related gene as a nonclassical peroxisome proliferator. J Cell Biol 2005 ; 169 : 93–104. [CrossRef] [PubMed] [Google Scholar]
  33. Gueugnon F, Gondcaille C, Leclercq S, et al. Dehydroepiandrosterone up-regulates the adrenoleukodystrophy-related gene (ABCD2) independently of PPARalpha in rodents. Biochimie 2007 ; 89 : 1312–1321. [CrossRef] [PubMed] [Google Scholar]
  34. Lopez-Erauskin J, Fourcade S, Galino J, et al. Antioxidants halt axonal degeneration in a mouse model of X-adrenoleukodystrophy. Ann Neurol 2011 ; 70 : 84–92. [CrossRef] [PubMed] [Google Scholar]
  35. Cartier N, Hacein-Bey-Abina S, Bartholomae CC, et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 2009 ; 326 : 818–823. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.